SG11201404180RA - Cho-gmt recombinant protein expression - Google Patents

Cho-gmt recombinant protein expression

Info

Publication number
SG11201404180RA
SG11201404180RA SG11201404180RA SG11201404180RA SG11201404180RA SG 11201404180R A SG11201404180R A SG 11201404180RA SG 11201404180R A SG11201404180R A SG 11201404180RA SG 11201404180R A SG11201404180R A SG 11201404180RA SG 11201404180R A SG11201404180R A SG 11201404180RA
Authority
SG
Singapore
Prior art keywords
gmt
cho
protein expression
recombinant protein
recombinant
Prior art date
Application number
SG11201404180RA
Inventor
Zhiwei Song
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SG2012004834A external-priority patent/SG192303A1/en
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG11201404180RA priority Critical patent/SG11201404180RA/en
Publication of SG11201404180RA publication Critical patent/SG11201404180RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001172—Sialyl-Thomson-nouvelle antigen [sTn]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/46447—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
SG11201404180RA 2012-01-20 2013-01-18 Cho-gmt recombinant protein expression SG11201404180RA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG11201404180RA SG11201404180RA (en) 2012-01-20 2013-01-18 Cho-gmt recombinant protein expression

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SG2012004834A SG192303A1 (en) 2012-01-20 2012-01-20 Cho-gmt recombinant protein expression
SG2012070652 2012-09-24
PCT/SG2013/000023 WO2013109190A2 (en) 2012-01-20 2013-01-18 Cho-gmt recombinant protein expression
SG11201404180RA SG11201404180RA (en) 2012-01-20 2013-01-18 Cho-gmt recombinant protein expression

Publications (1)

Publication Number Publication Date
SG11201404180RA true SG11201404180RA (en) 2014-08-28

Family

ID=54259029

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201507721SA SG10201507721SA (en) 2012-01-20 2013-01-18 CHO-GMT Recombinant Protein Expression
SG11201404180RA SG11201404180RA (en) 2012-01-20 2013-01-18 Cho-gmt recombinant protein expression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201507721SA SG10201507721SA (en) 2012-01-20 2013-01-18 CHO-GMT Recombinant Protein Expression

Country Status (6)

Country Link
US (1) US20150119558A1 (en)
EP (1) EP2804946A4 (en)
KR (1) KR20140124789A (en)
CN (1) CN104487570A (en)
SG (2) SG10201507721SA (en)
WO (1) WO2013109190A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170321240A1 (en) * 2014-10-27 2017-11-09 Agency For Science, Technology And Research Glycosylation mutants for producing galactose-free and fucose-free polypeptides
IL276165B (en) * 2014-12-01 2022-11-01 Amgen Inc Process for manipulating the level of glycan content of a glycoprotein
CN108220307B (en) * 2018-01-17 2020-02-21 中国科学院华南植物园 GDP-mannose transport protease and coding gene and application thereof
CN112001329B (en) * 2020-08-26 2021-11-30 深圳太力生物技术有限责任公司 Method and device for predicting protein expression amount, computer device and storage medium

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034829A1 (en) * 2001-12-27 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
US20060024292A1 (en) * 2001-12-27 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
EP1829961A4 (en) * 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd Method of preparing antibody by use of cell having its fucose transporter function inhibited
WO2008040362A2 (en) * 2006-10-04 2008-04-10 Københavns Universitet Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
US9175278B2 (en) * 2010-03-25 2015-11-03 Agency For Science, Technology And Research Method of producing recombinant proteins with mannose-terminated N-glycans

Also Published As

Publication number Publication date
EP2804946A4 (en) 2016-05-25
EP2804946A2 (en) 2014-11-26
WO2013109190A2 (en) 2013-07-25
US20150119558A1 (en) 2015-04-30
WO2013109190A3 (en) 2015-01-29
KR20140124789A (en) 2014-10-27
CN104487570A (en) 2015-04-01
SG10201507721SA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
HRP20190454T1 (en) Recombinant factor viii proteins
EP2929045A4 (en) Protein expression enhancing polypeptides
EP2857033A4 (en) Skin-permeating peptide
EP2812347A4 (en) Autophagy-inducing peptide
HK1207120A1 (en) Improved harvest operations for recombinant proteins
SG11201404180RA (en) Cho-gmt recombinant protein expression
HK1209138A1 (en) Peptides
HK1204948A1 (en) Radiation-sterilization-resistant protein composition
EP3560952C0 (en) Variant of bpifb4 protein
GB201204868D0 (en) Peptides
GB201200555D0 (en) Peptide
GB201304973D0 (en) Recombinant protein
GB201223114D0 (en) Novel peptide
HK1201752A1 (en) Alternaria peptides
GB201213672D0 (en) Protein
PT2891663T (en) Psf1-derived peptides
HK1211952A1 (en) Recombinant protein
GB201210286D0 (en) Recombinant polypeptide
GB201215901D0 (en) Protein modification
GB201200743D0 (en) Protein bridges
GB201220328D0 (en) Peptides
GB201221414D0 (en) Trans-locating peptide
GB201211740D0 (en) Peptides
GB201207895D0 (en) Peptides
GB201200509D0 (en) Peptides